Showing 1 posts of 1 posts found.
Astellas Pharma has abandoned the development of its oral direct factor Xa inhibitor darexaban. The Japanese firm blamed both the …
Santen joins inaugural Global Summit for Eye Health as partner
EHP Awards 2027 open for entries following outstanding inaugural year
NHS spends £240m storing patient records as digital reforms gather pace
NHS awards national diabetes education contract to Leicester programme
InnoScot highlights NHS Scotland’s progress towards net zero healthcare